RegeneRx

Shareholder letter - Tuesday February 17, 2015

Link to document.

RegeneRx Pipeline

RegeneRx Biopharmaceuticals, Inc. is a clinical-stage drug development company focused on tissue protection, repair and regeneration with an extensive portfolio of product candidates for first-in-class therapeutic peptides.

Latest News:

May 27, 2016
RegeneRx Comments on Valuation


May 17, 2016
RegeneRx Releases Letter to Stockholders


May 10, 2016
Rodman & Renshaw Updates Analyst Report on RegeneRx Biopharmaceuticals, Inc. with Buy Rating


May 6, 2016
RGN-259 Confirms Efficacy in Signs and Symptoms of Dry Eye


April 28, 2016
RegeneRx and ReGenTree Expand License for Dry Eye


April 6, 2016
RegeneRx to Receive EU Patent for Use of Tβ4 in Preventing And Treating Damage Associated with Reperfusion Injury